Work

Randomized phase II (RP2) study of ATR inhibitor M6620 in combination with gemcitabine versus gemcitabine alone in platinum-resistant high grade serous ovarian cancer (HGSOC)

Year: 2019

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: Annals of Oncology

DOI: 10.1093/annonc/mdz394.057

Authors: P.A. Konstantinopoulos, A.E. Wahner Hendrickson, R.T. Penson, A. Doyle, E.C. Kohn, L.R. Duska, M.A. Crispens, A.B. Olawaiye, I.S. Winer, L.M. Barroilhet, S. Fu, M.T. McHale, R.J. Schilder, A. Farkkila, J. Curtis, R. Quinn, C. Whalen, G.I. Shapiro, U.A. Matulonis

Institutions: Dana-Farber Cancer Institute, Mayo Clinic, Massachusetts General Hospital, National Cancer Institute, University of Virginia Cancer Center, Vanderbilt University, Vanderbilt-Ingram Cancer Center, UPMC Hillman Cancer Center, The Barbara Ann Karmanos Cancer Institute, University of Wisconsin–Madison, UW Health University Hospital, The University of Texas MD Anderson Cancer Center, Moores Cancer Center, Thomas Jefferson University Hospital

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2977445291

FWCI: 0.995

Cites:

Cited by: 5

Related to: 10